Helus Pharma (HELP) Stock Forecast & Price Target

2,534 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

HELP Analyst Ratings

Strong Buy

6 Buy

0 Hold

0 Sell

Based on 6 analysts giving stock ratings to

Helus

Pharma

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

HELP Stock 12 Month Forecast

Average Price Target

$35.33

▲(542.42% Upside)

Based on 6 Wall Street analysts offering 12 month price targets for Helus Pharma in the last 3 months. The average price target is $35.33 with a high forecast of $70.00 and a low forecast of $15.00. The average price target represents a 542.42% change from the last price of $5.50.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3":"$3","20":"$20","37":"$37","54":"$54","71":"$71"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":70,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$70.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":35.333333333333336,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$35.33</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":15,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$15.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3,20,37,54,71],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.82,12.603076923076923,17.386153846153846,22.16923076923077,26.95230769230769,31.735384615384614,36.51846153846154,41.30153846153846,46.08461538461538,50.8676923076923,55.65076923076923,60.433846153846154,65.21692307692308,{"y":70,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.82,9.936410256410257,12.052820512820514,14.16923076923077,16.285641025641027,18.402051282051282,20.51846153846154,22.6348717948718,24.751282051282054,26.86769230769231,28.984102564102567,31.100512820512826,33.21692307692308,{"y":35.333333333333336,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.82,8.372307692307693,8.924615384615384,9.476923076923077,10.02923076923077,10.581538461538461,11.133846153846154,11.686153846153847,12.23846153846154,12.79076923076923,13.343076923076923,13.895384615384614,14.447692307692307,{"y":15,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":7.56,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.24,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.98,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.26,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.18,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.87,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.61,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.99,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.15,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.69,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.28,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.82,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$70.00

Average Price Target$35.33

Lowest Price Target$15.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Sumant Kulkarni

Canaccord Genuity

$42

Buy

663.64%

Upside

Reiterated

08/03/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Arvinas Holding Company (NASDAQ: ARVN), Certara (NASDAQ: CERT) and Helus Pharma (NASDAQ: HELP)

Benjamin Burnett

Wells Fargo

$16

Buy

190.91%

Upside

Initiated

07/27/26

Helus Pharma initiated with an Overweight at Wells FargoHelus Pharma initiated with an Overweight at Wells Fargo

Patrick Trucchio

H.C. Wainwright

$70

Buy

1172.73%

Upside

Reiterated

07/21/26

Helus Pharma: Late-Stage Psychedelic Depression Data Seen as Near-Term Catalyst; Buy Rating Reaffirmed with Unchanged $70 Target

David Martin PhD

Bloom Burton

$47

Buy

754.55%

Upside

Reiterated

07/21/26

Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (NYSE: JNJ), Helus Pharma (NASDAQ: HELP) and Nektar Therapeutics (NASDAQ: NKTR)

James Molloy

Alliance Global Partners

$30→$15

Buy

172.73%

Upside

Reiterated

07/14/26

Helus Pharma price target lowered to $15 from $30 at Alliance GlobalHelus Pharma price target lowered to $15 from $30 at Alliance Global

Andrew Tsai

Jefferies

$22

Buy

300.00%

Upside

Reiterated

06/25/26

Jefferies Sticks to Their Buy Rating for Helus Pharma (HELP)

Ritu Baral

TD Cowen

Buy

45.45%

Upside

Initiated

04/13/26

Analysts Conflicted on These Healthcare Names: Johnson & Johnson (NYSE: JNJ), BeOne Medicines (NASDAQ: ONC) and Helus Pharma (NASDAQ: HELP)

Eddie Hickman

Guggenheim

$39→$48

Buy

772.73%

Upside

Reiterated

12/03/25

Cybin price target raised to $48 from $39 at GuggenheimCybin price target raised to $48 from $39 at Guggenheim

Pete Stavropoulos

Cantor Fitzgerald

―

Buy

―

Reiterated

10/15/25

Cantor Fitzgerald Keeps Their Buy Rating on Cybin (CYBN)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Sumant Kulkarni

Canaccord Genuity

$42

Buy

663.64%

Upside

Reiterated

08/03/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Arvinas Holding Company (NASDAQ: ARVN), Certara (NASDAQ: CERT) and Helus Pharma (NASDAQ: HELP)

Benjamin Burnett

Wells Fargo

$16

Buy

190.91%

Upside

Initiated

07/27/26

Helus Pharma initiated with an Overweight at Wells FargoHelus Pharma initiated with an Overweight at Wells Fargo

Patrick Trucchio

H.C. Wainwright

$70

Buy

1172.73%

Upside

Reiterated

07/21/26

Helus Pharma: Late-Stage Psychedelic Depression Data Seen as Near-Term Catalyst; Buy Rating Reaffirmed with Unchanged $70 Target

David Martin PhD

Bloom Burton

$47

Buy

754.55%

Upside

Reiterated

07/21/26

Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (NYSE: JNJ), Helus Pharma (NASDAQ: HELP) and Nektar Therapeutics (NASDAQ: NKTR)

James Molloy

Alliance Global Partners

$30→$15

Buy

172.73%

Upside

Reiterated

07/14/26

Helus Pharma price target lowered to $15 from $30 at Alliance GlobalHelus Pharma price target lowered to $15 from $30 at Alliance Global

Andrew Tsai

Jefferies

$22

Buy

300.00%

Upside

Reiterated

06/25/26

Jefferies Sticks to Their Buy Rating for Helus Pharma (HELP)

Ritu Baral

TD Cowen

Buy

45.45%

Upside

Initiated

04/13/26

Analysts Conflicted on These Healthcare Names: Johnson & Johnson (NYSE: JNJ), BeOne Medicines (NASDAQ: ONC) and Helus Pharma (NASDAQ: HELP)

Eddie Hickman

Guggenheim

$39→$48

Buy

772.73%

Upside

Reiterated

12/03/25

Cybin price target raised to $48 from $39 at GuggenheimCybin price target raised to $48 from $39 at Guggenheim

Pete Stavropoulos

Cantor Fitzgerald

―

Buy

―

Reiterated

10/15/25

Cantor Fitzgerald Keeps Their Buy Rating on Cybin (CYBN)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

AVBPArriVent BioPharma, Inc.

BTSGBrightSpring Health Services, Inc.

MLYSMineralys Therapeutics, Inc.

ZURAZura Bio

TNYATenaya Therapeutics

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Helus Pharma

3 Months

Sumant KulkarniCanaccord Genuity

Success Rate

9/19 ratings generated profit

Average Return

+0.68%

Copying Sumant Kulkarni's trades and holding each position for 3 Months would result in 47.37% of your transactions generating a profit, with an average return of +0.68% per trade.

1 Year

Patrick TrucchioH.C. Wainwright

Success Rate

8/16 ratings generated profit

Average Return

-4.23%

Copying Patrick Trucchio's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of -4.23% per trade.

2 Years

Patrick TrucchioH.C. Wainwright

Success Rate

10/16 ratings generated profit

Average Return

+2.74%

Copying Patrick Trucchio's trades and holding each position for 2 Years would result in 62.50% of your transactions generating a profit, with an average return of +2.74% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

HELP Analyst Recommendation Trends

Rating

Apr 26

May 26

Jun 26

Jul 26

Aug 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, HELP has received 9 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. HELP average Analyst price target in the past 3 months is 35.33.

Each month's total comprises the sum of three months' worth of ratings.

HELP Financial Forecast

HELP Earnings Forecast

The previous quarter’s earnings for HELP were -$0.95.

No data currently available

HELP Sales Forecast

The previous quarter’s earnings for HELP were $0.00.

HELP Stock Forecast FAQ

What is HELP’s average 12-month price target, according to analysts?

Based on analyst ratings, Helus Pharma’s 12-month average price target is 35.33.

What is HELP’s upside potential, based on the analysts’ average price target?

Helus Pharma has 542.42% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is HELP a Buy, Sell or Hold?

Helus Pharma has a consensus rating of Strong Buy which is based on 6 buy ratings, 0 hold ratings and 0 sell ratings.

What is Helus Pharma’s price target?

The average price target for Helus Pharma is 35.33. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $70.00 ,the lowest forecast is $15.00. The average price target represents 542.42% Increase from the current price of $5.5.

What do analysts say about Helus Pharma?

Helus Pharma’s analyst rating consensus is a Strong Buy. This is based on the ratings of 6 Wall Streets Analysts.

How can I buy shares of HELP?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Helus Pharma (HELP) Stock Forecast & Price Target

HELP Analyst Ratings

HELP Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Helus Pharma

HELP Analyst Recommendation Trends

HELP Financial Forecast

HELP Earnings Forecast

HELP Sales Forecast

HELP Stock Forecast FAQ

Detailed List of Analyst Forecasts